The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT in non-melanoma skin cancer patients.

OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT.

The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of non-melanoma skin cancers. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patients' skin

The EPIC Skin study aims to further evaluate the efficacy of Rhenium-SCT as well as important Patient Reported Outcome Measures such as quality of life, treatment comfort and cosmetic outcomes.

The study will enroll a minimum number of 175 adult patients with a confirmed histologically of stage I or II non-melanoma skin cancer to participate for 12 months, with a follow up period to 24 months. Study centres participating in the initiative are located in Australia, Austria, Germany and the United Kingdom. 

Enrollment for the EPIC-Skin trial is expected to open as soon as November 2021.

"Rhenium-SCT has proven to be effective and safe in previous studies,” says Dr. Gerhard Dahlhoff, Medical Director at OncoBeta GmbH, in a news releases. “Wit this new study we want to further evaluate the efficacy and safety of the Rhenium-SCT® at an international level in NMSC patients. This will be done in different centres under the same conditions."

"The initiation of the EPIC-Skin Study is a significant milestone for the Rhenium-SCT," says Shannon D. Brown III, CEO and Managing Director at OncoBeta GmbH. "This will further demonstrate how effective and safe this therapy is. Furthermore, aligning with our company vision of focussing on quality of life, this study will also report on outcomes from the patient's perspective."